We are live on ! Find out more
INDP icon

Indaptus Therapeutics
INDP

9 hedge funds and large institutions have $1.15M invested in Indaptus Therapeutics in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

798% more capital invested

Capital invested by funds: $129K → $1.15M (+$1.03M)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

50% more funds holding

Funds holding: 6 → 9 (+3)

2.81% less ownership

Funds ownership: 3.15% → 0.34% (-2.8%)

Holders
9
Holders Change
+3
Holders Change %
+50%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$519K
2
Jane Street
Jane Street
New York
+$135K
3
Vanguard Capital Management
Vanguard Capital Management
Pennsylvania
+$84.7K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$74.2K
5
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust
Pennsylvania
+$35.2K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$71K
2
TRCT
Tower Research Capital (TRC)
New York
-$3.44K

INDP Hedge Fund Activity: Q2 2026 in Review

9 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q2 2026, worth a combined $1.15M — up 798% from $129K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new INDP positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $519K. The largest seller was Citadel Advisors, exiting entirely with an estimated $71K sold.

  • 9 institutional investors held Indaptus Therapeutics (INDP) as of Q2 2026, up from 6 in Q1 2026.
  • Funds reported $1.15M of Indaptus Therapeutics stock for Q2 2026, up 798% quarter-over-quarter.
  • 6 funds opened new Indaptus Therapeutics positions in Q2 2026 and 2 closed out, a net change of +4 holders.
  • The largest Indaptus Therapeutics buyer in Q2 2026 was HRT Financial, an estimated $519K added.
  • The largest Indaptus Therapeutics seller in Q2 2026 was Citadel Advisors, an estimated $71K sold.

Based on aggregated 13F filings for Q2 2026.